iSERA Lifesciences Limited has received shareholder approval for a series of strategic resolutions following the conclusion of its postal ballot process through remote e-voting. The scrutinizer's report confirms that all seven proposed resolutions were passed with the requisite majority on May 21, 2026. The voting process was managed by MIPL via a designated e-voting platform, with participation from members holding shares as of the cut-off date of April 17, 2026.

Key Resolutions Approved

The resolutions covered significant corporate actions, including alterations to the company's capital structure and governance documents. Shareholders authorized an increase in the authorised share capital and the consequential alteration of the capital clause in the Memorandum of Association. Furthermore, the company approved the adoption of a new set of Memorandum of Association and Articles of Association, substituting the existing documents to align with the provisions of the Companies Act, 2013.

Acquisition and Capital Expansion

A major outcome of the ballot was the approval for the acquisition of up to 100% equity shareholding in iSERA Biological Limited, a target company, through a share swap. This included a specific resolution approving the related party transaction for the acquisition. To facilitate this, shareholders also authorized the issuance of equity shares via preferential issue on a private placement basis for consideration other than cash, specifically through the share swap mechanism. Additionally, the company received approval to enhance limits for making investments, giving loans, or providing securities under Section 186 of the Companies Act, 2013.

Voting Results Summary

The remote e-voting period commenced on April 22, 2026, and concluded on May 21, 2026. The scrutinizer's report details the voting patterns across different categories of shareholders. The resolutions received strong support, with the acquisition-related resolutions securing 100% of the votes polled. The table below summarizes the voting results for the key resolutions.

Shareholder Participation

The voting process saw participation from 31 members for the acquisition resolutions, while other resolutions saw participation ranging from 29 to 30 members. The Promoter and Promoter Group voted in favour of all resolutions, holding 4,930,000 shares. Public Non-Institutional shareholders also participated significantly, with 3,478,972 shares held. No physical postal ballots were dispatched, as per the relevant MCA Circulars, and all voting was conducted electronically. The records related to this postal ballot activity will be handed over to the authorised person of the company for safekeeping.

iSERA Lifesciences Limited has approved its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors met on May 21, 2026, to consider and approve the results, which were reviewed by the audit committee. The statutory auditor, GMKS & Co., issued an audit report with an unmodified opinion for the period.

The company reported a revenue from operations of INR 135.50 lakh for the year ended March 31, 2026, compared to INR 26.52 lakh in the previous year. Total income for the year stood at INR 142.52 lakh. The company posted a profit for the year of INR 25.94 lakh, a significant increase from the profit of INR 11.81 lakh in the prior year. Earnings per share (EPS) for the year were recorded at INR 0.74 on a basic and diluted basis.

Financial Performance

The company’s expenses for the year totaled INR 108.88 lakh. Direct expenses accounted for INR 45.00 lakh, while employee benefits expense was INR 5.25 lakh. Other expenses, which include right issue expenses of INR 42.25 lakh, amounted to INR 58.63 lakh. The finance costs were nil for the period.

Capital Structure and Rights Issue

During the year, the company allotted 80,85,550 equity shares of face value INR 10 each at par, pursuant to a rights issue aggregating to INR 8,08,55,500. The shares were issued in the ratio of 25 equity shares for every 1 fully paid-up equity share held. The issued, subscribed, and paid-up equity share capital as of March 31, 2026, stood at INR 840.90 lakh, comprising 84,08,972 equity shares.

The company’s net worth and paid-up equity share capital were below the thresholds of INR 10 crore and INR 25 crore respectively as of March 31, 2025. Consequently, the company is exempt from complying with certain corporate governance requirements specified in SEBI (LODR) Regulations, 2015.